Darin Ramsey, PharmD, BCPS, BCACP

• Associate Professor of Pharmacy Practice, Butler University College of Pharmacy & Health Sciences
• Clinical Specialist in Primary Care, Richard L. Roudebush VA Medical Center, Indianapolis, Indiana

The effect of hydralazine on placental perfusion in the spontaneously hypertensive rat glyset 50 mg purchase without prescription. Amiodarone-induced neonatal hypothyroidism: a unique form of transient early-onset hypothyroidism buy cheap glyset on-line. Clinical course of fetal congenital atrioventricular block in the Japanese population: a multicentre experience glyset 50 mg order overnight delivery. The safety of calcium channel blockers in human pregnancy: a prospective buy glyset australia, multicenter cohort study generic 50 mg glyset with amex. Risks and benefits of beta-receptor blockers for pregnancy hypertension: overview of the randomized trials. Randomized comparison of calcium antagonists and beta-blockers in the treatment of pregnancy-induced hypertension. Randomised controlled trial of methyldopa and isradipine in preeclampsia ­ effects on uteroplacental and fetal hemodynamics. A comparative study of the use of epoprostenol and dihydralazine in severe hypertension in pregnancy. Pregnancy with prolonged fetal exposure to an angiotensinconverting enzyme inhibitor. Can magnesium sulfate reduce the risk of cerebral palsy in very low birth-weight infants Diazoxide for the acute control of severe hypertension complicating pregnancy: a pilot study. Asymptomatic paroxysmal atrial fibrillation during intravenous magnesium sulfate treatment in pre-eclampsia. Hypertension during pregnancy with and without specific treatment; the development of the children at the age of four years. Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomised controlled trials. Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial. Calcium channel blockers in the management of preterms labor and hypertension in pregnancy. Role of calcium in the induction of cardiac hypertrophy and myofibrillar disarray. A randomized placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Maternal effects and perinatal safety of labetalol in the treatment of hypertension in pregnancy. A randomized comparison of early with conservative use of antihypertensive drugs in the management of pregnancy-induced hypertension. Fetal supraventricular tachycardia diagnosed and treated at 13 weeks of gestation: a case report. The Parkland Memorial Hospital protocol for treatment of eclampsia: evaluation of 245 cases. First year of life after the use of atenolol in pregnancy associated hypertension. Treatment of hypertension during pregnancy with hydralazine monotherapy or with combined therapy with hydralazine and pindolol. Clinical pharmacological studies with prazosin during pregnancy complicated by hypertension. Reproduction studies of Amezinium metisulfate(4) ­ teratogenicity study in rabbits. Congenital hypertrophic cardiomyopathy associated with in utero verapamil exposure. Sodium nitroprusside for control of severe hypertensive disease of pregnancy: a case report and discussion of potential toxicity. Fetal distress after hydralazine therapy for severe pregnancy-induced hypertension. Acute effects of dihydralazine mesylate, furosemide, and metoprolol on maternal hemodynamics in pregnancy-induced hypertension. Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment. Neonatal suppurative parotitis possibly associated with congenital cytomegalovirus infection and maternal methyldopa administration. Acute pulmonary oedema during nicardipine therapy for premature labour report of five cases. A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. Do commonly used oral antihypertensives alter fetal or neonatal heart rate characteristics Pregnancy outcome after exposure to calcium-channel blockers during first trimester. Chronic measurement, using a Doppler probe, of uterine artery flow in the gravid guinea-pig. Pulmonary vascular disease and pregnancy: currrent controversies, management strategies, and perspectives. Lupus-like syndrome in a mother and newborn following administration of hydralazine: a case report. As described historically by Virchow, there are, in his opinion, three factors that predispose an individual to the development of venous thrombosis: hypercoagulability, vascular damage, and stasis. Fibrinolytic activity decreases due to the increased levels of plasminogen activator inhibitors produced by the placenta. These changes represent the physiological preparation for the hemostatic challenge of delivery (Greer 1999, Dizon-Townson 1998). In addition, venous flow decreases from the lower extremities (stasis), and delivery and placental separation create vascular damage (Dizon-Townson 1998). Management of pregnant women with thrombophilias is still subject to debate in the recent literature (see section 2. Universal agreement regarding thromboprophylaxis during pregnancy has not been established to date, because of the lack of reliable data on the specific risks and the efficacy of thromboprophylaxis. A prior thrombotic event or thrombophilia is not currently viewed by all clinicians as an indication for thromboprophylaxis during pregnancy (see section 2. When administered in prophylactic, low dosages (subcutaneous), it is mainly factor Xa that is neutralized; in higher therapeutic dosages, thrombin will also be neutralized. Heparins can initiate plasminogen activator release by endothelial cells, and this accounts for their fibrinolytic activity. Heparins are broken down in the gut, and require a parenteral route of administration (intravenous or subcutaneous). They have a poor bioavailabilty (10%), are metabolized in the liver, and have a half-life of about 4­6 hours. Heparin does not cross the placental barrier due to its high molecular weight and its negative charge. They are heparin fragments produced by chemical or enzymatic depolymerization, and their molecular weight ranges from 4000­6000 daltons. Long-term heparin therapy (>1 month) may be associated with increased bone loss, particularly during pregnancy, which is probably a cause of reversible bone demineralization in itself. Low molecular-weight heparins have now largely replaced unfractioned heparin, because of their improved safety profile. This was confirmed in several publications, which included the use of enoxaparin, dalteparin, nadroparin, tinzaparin, and certoparin. At present, thromboprophylaxis during pregnancy is still controversial (Cetin 2005, Bates 2004, Greer 2003, Brenner 2003, Gebhardt 2003). However, consensus has been reached on thromboprophylaxis for recurrent pregnancy loss in patients with antiphospholipid syndrome. No definitive recommendations can be given for the treatment of pregnant women with inherited thrombophilias or with mechanical heart valves. This therapy (preferably in combination with low molecularweight heparins) is found to be effective in preventing recurrent pregnancy loss and other pregnancy complications in women with antiphospholipid syndrome, as in systemic lupus erythematosus (see also Chapter 2. In one meta-analysis, aspirin treatment seemed to have, for women with moderate and high risk, a small but significant effect on reducing the rate of preterm birth, but it did not reduce the rate of perinatal death (Kozer 2003). The use of lowdose aspirin for preventing recurrent pregnancy loss and other serious obstetrical complications in women with thrombophilia remains a subject for debate (Robertson 2005, Bates 2004, Gris 2004, Brenner 2003). No adverse effects in the mother, fetus or newborn in association with the use of low-dose aspirin were observed. Danaparoid is a heparinoid with a molecular weight of about 6500 daltons, and, based upon molecular weight and similar compounds, it is likely 242 2. In a recent review, use in pregnancy was evaluated; no indications of increased risk of adverse fetal outcome were observed (Lindhoff-Last 2005). It has, combined with other anticoagulants, also been investigated in women with essential thrombocythemia, in attempts to reduce the incidence of recurrent abortions and fetal growth retardation. Unfortunately, data are insufficient for an opinion about its safety (Eliyahu 1997). Abciximab, clopidogrel, eptibatide, ticlopidine, and tirofiban antagonize platelet aggregation. However, it was demonstrated that abciximab did not cross the in vitro perfused human placental lobule because it was degraded by the placenta since it is a chimearic Fab fragment (Miller 2003). When one of the other abovementioned antithrombotics has been used during the first trimester, the termination of pregnancy or invasive diagnostics are not required. Coumarin derivatives are nearly totally resorbed in the gut and are bound to albumin by more than 95%. Because the action of the drug is based on inhibition of the synthesis of the coagulation factors, it takes 1­3 days before blood concentrations are effectively lowered and the drug becomes effective. Interaction with other drugs can occur through competition, oxidating enzymes in the liver as well as binding to plasma proteins. Toxicology the embryotoxic properties of coumarins have been established in humans. The rate of spontaneous abortion is also increased (Schaefer 2006, Blickstein 2002, Bates 1997, Pauli 1993, Hall 1980). To estimate the prevalence of congenital anomalies associated with coumarin exposure during pregnancy, van Driel (2002A) reviewed 17 studies describing a total of 979 pregnancies, of which 449 involved acenocoumarol, 327 warfarin, and 203 an unspecified coumarin). Twenty-three children had skeletal anomalies, interpreted as indicative for coumarin embryopathy, of 394 children born alive to mothers using coumarins throughout pregnancy (6%). Considering the pathogenetic mechanisms discussed in the context of warfarin, it can be assumed that all coumarins and indanediones have a similar teratogenic and fetotoxic potential. The most consistent clinical feature was mid-face hypoplasia (n 47), including a depressed nasal bridge, underdevelopment or absence of the nasal septum, a small, upturned nose with grooves between the tip of the nose and the alae nasi, micrognathia, a prominent forehead, and a flat appearance of the face. Stippling in the epiphyseal regions (chondrodysplasia punctata) was described in 32 of the 63 cases, mostly along the axial skeleton, at the proximal femora and in the calcanei (Hall 1980). The possible mechanisms for this effect are thought to be the inhibition of the enzyme arylsulfatase and inhibition of the synthesis of vitamin K-dependent (non-coagulant) proteins, thus interfering with normal bone and cartilage development. Limb hypoplasia, primarily involving the distal digits, may be seen in up to one-third of children with warfarin embryopathy (Pauli 1993). Other abnormalities that have been associated with the coumarin embryopathy are 2 Pregnancy 2. Furthermore, there were a few cases reporting dysgenesis of the eye, cardiac defects (tetralogy of Fallot, persistent truncus arteriosus, and atrial septal defects), asplenia syndrome, absence of a kidney, cleft lip and palate, hypoplasia of the lungs with absence of the right diaphragm, and situs inversus. In addition, 13 cases of minor physical anomalies were reported, including lowset or poorly developed ears, a high-arched palate, hypertelorism, antimongoloid palpebral fissures, and widely spaced nipples. Those five case reports cited in the literature as indicative for an embryopathy risk associated with exposure exclusively at week 8 were either calculated in weeks after conception (Hall 1989, Balde 1988), or causality was doubtful (Ruthnum 1987, Cox 1977) and/or additional contributing factors were reported (Lapiedra 1986). The sequelae of intracerebral bleeding appear to be more debilitating than those of the coumarin embryopathy; intracranial bleeding during delivery is especially to be feared. To study long-term effects, van Driel (2003B, 2001) and Wesseling and co-workers (2001, 2000) compared a coumarin exposed cohort of about 300 children aged from 7. There were only two children in the exposed cohort with signs of coumarin embryopathy. The mean height and overall growth of exposed children did not differ from those of the unexposed children. However, there was a slightly increased risk for minor neurological dysfunction after exposure during the second or third trimester (Wesseling 2001). In view of possible fetal embryopathy and other adverse effects, coumarin derivatives are not recommended in the first trimester or at the end of pregnancy, and generally are not recommended 2. However, less favorable task-oriented and social­emotional behavior was observed among the exposed cohort (van Driel 2001). Three other follow-up studies with a total of 72 children could not find significant differences in physical or mental development (Olthof 1994, Wong 1993, Chong 1984). The largest controlled, prospective study until now includes 666 pregnancies with 670 exposures to different vitamin K antagonists. In this multicenter study, pregnancies were compared, with respect to their outcome, with 1049 controls. This study confirmed the teratogenicity of coumarins, and revealed a three-fold miscarriage rate after firsttrimester treatment. The risk for coumarin embryopathy seems to be small, however, and the outcomes of this study confirmed that when exposure was limited to the first 6 (postconceptional) weeks, the risk of major malformations did not appear to be substantially increased (Peters 2006, Schaefer 2006). Adverse outcome was suggested to be dose-dependent (more than 5 mg/day) in a small study of 52 patients with mechanical heart valves who had been exposed to warfarin during 71 pregnancies (Cotrufo 2002). Several studies indicate that the choice of anticoagulant regimens for mechanical heart valve thromboprophylaxis during pregnancy should be made by balancing two risks: maternal morbidity and mortality from thromboembolic complications on the one hand, and fetal loss and embryopathy on the other ­ which means choosing between coumarin therapy throughout pregnancy, or substitution with adjusted-dose heparin between weeks 6 and 12. The dosage necessary to keep satisfactory levels of anticoagulation and thrombotic risks associated with specific valves are parameters to be reckoned with (Bates 2004, Cotrufo 2002, Chan 2000, Vitale 2000): maternal risk should be weighed against a possible fetal risk. In high-risk patients with mechanical heart valves, an exception may be necessary because of maternal health requirements; here, oral anticoagulants throughout pregnancy until near term may need to be considered. The risk for coumarin embryopathy is small, in particular when therapy during the first trimester did not take place later than week 8 after the first day of last menstruation; therefore, elective termination of a wanted pregnancy is not recommended if (inadvertent) exposure took place in early pregnancy. Vitamin K1 (phytomenadione, phytonadione, phylloquinone) is found in plants; vitamin K2 is synthesized from vitamin K1 by various bacteria in adult intestines; vitamin K3 (menadione) is a synthetic analog of vitamin K1; and vitamin K4 is the water-soluble form of menadione. Under normal conditions, there is no need for the administration of vitamin K in pregnant women because gastrointestinal bacteria supply adequate amounts.

When dietary measures are really insufficient generic glyset 50 mg mastercard, loperamide may be taken temporarily during breastfeeding order 50 mg glyset with amex. However 50 mg glyset buy, the essential oil could glyset 50 mg without a prescription, in individual instances buy discount glyset line, affect the taste of the milk and lead to a (temporary) nursing strike. Dimeticon or simeticon and vegetable preparations can be given for flatulence without reservation. Lipid reducers should not be used during breastfeeding because their safety is not established, and there would seem to be no disadvantage for the mother when therapy is stopped during pregnancy and breastfeeding. Taking the medication, however, does not require any limitation of breastfeeding, although, with the exception of colestipol, cholestyramine, and pravastatin, the continuation of treatment should be critically reviewed. Chenodeoxycholic acid and ursodeoxycholic acid should not be used while breastfeeding. Only limited amounts of ursodeoxycholic acid appear in the blood circulation, where they are overwhelmingly bound to albumin. Lactation Pravastatin appears only in negligible amounts in the milk (less than 0. No toxic effects on the infant have been reported as yet in connection with maternal intake of lipid reducers. However, the documented experience with acipimox, atorvastatin, bezafibrate, cerivastatin, clofibrate, colestipol, cholestyramine, etofibrate, etofyllinclofibrate, ezetimibe, fenofibrate, fluvastatin, gemfibrozil, inositol nicotinate, lovastatin, pitavastatin, pravastatin, probucol, rosuvastatin, simvastatin, -sitosterin, and xantinol nicotinate is insufficient for a risk assessment. Due to the way they work, the lipid-binding resins colestipol and cholestyramine, which are not absorbed in significant amounts, are not considered to pose a risk to the breastfed infant. The accidental intake of a single dose does not require limitation of breastfeeding. Very rarely, mild restlessness, sedation or weak sucking ­ none of which require treatment ­ have been described in the breastfed infant (see, for example, Moretti 1995). The brief half-life of 2­3 hours and the long effectiveness of up to 24 hours argue for good tolerance of meclizine during pregnancy. Even with the other, older antiemetics, including the phenothiazine-neuroleptics which are used for this purpose, severe intolerance in the infant ­ especially after single dosages ­ would not be expected. If a serotonin antagonist such as ondansetron is indicated during lactation, the child should be observed for unexpected symptoms. Induction of lactation in the intended mother of a surrogate pregnancy: case report. Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid preparations. Effect of domperidone on milk production in mothers of premature newborns: a randomized, double-blind, placebo-controlled trial. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal infection. Metoclopramide and breast-feeding: efficacy and anterior pituitary responses of the mother and the child. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. Thus, in any case, only minimal concentrations are reached in the infant plasma, and in no case is a concentration reached that would inhibit bacterial growth. The following risks have been discussed repeatedly in the literature: Effects on the intestinal flora (with diarrhea as a possible consequence) Effects on bacteriological studies which might be necessary in case the infant falls ill Development of bacterial resistance Sensitization. The likeliest possibility ­ in rare cases ­ would be a temporary loosening of the stool consistency, which does not require any therapy (Ito 1993). As a rule, the exclusively breastfed infant receives considerably less than 1% of a therapeutic dosage (survey in Bennett 1996). This applies similarly to cephalosporins, which are, to some extent, inactivated in the intestine (survey in Bennett 1996). Benyamini and co-workers asked 67 mothers who were taking amoxicillin plus the enzyme inhibitor clavulanic acid, as well as 38 who were taking cefuroxim, about side effects in their breastfed children (Benyamini 2005). With cefuroxim and cefalexin, only moderate side effects were reported and in scarcely 3% of cases. With sulbactam, the relative daily dosage transmitted was a maximum of 1% (Foulds 1985). This provides additional support for limited bioavailability to the breastfed child. Other -lactam antibiotics have not as yet been shown to be toxic for the breastfed infant. Penicillin derivatives and cephalosporins are the antibiotics of choice during breastfeeding. With 500 mg/daily of clarithromycin, used to treat a puerperal infection, a maximum of 1. There are no reports of specific intolerance during breastfeeding to any of the macrolides mentioned here. In addition to penicillin derivatives and cephalosporins, erythromycin and roxithromycin are the antibiotics of choice during breastfeeding. The macrolidic antibiotics, azithromycin, clarithromycin, josamycin, and spiramycin, are second-choice medications. Where there is already a noteworthy icterus in the first days of life, caution should be exercised if the mother receives high dosages of parenteral macrolides. With 200 mg of doxycycline therapy followed 24 hours later by a 100-mg dose, a maximum of 1. At most, 3­4% of the maternal weight-related dosage reaches the infant in this way. With chlortetracycline therapy, the dosage transported by the milk is under 1% (survey by Bennett 1996). Tetracyclines, including doxycycline and minocycline, can be given when success using the antibiotics of choice (see above) cannot be expected. Based on these values, the relative dose for a fully breastfed child can reach 10%. Haemolytic reaction of a baby with glucose6-phosphate-dehydrogenase deficiency was described in an older report. Apart from such a constellation, threatening effects are not to be expected for a breastfed child ­ particularly one who is older than 4 weeks. With sulfamethoxazole, the sulfonamide portion in cotrimoxazole is, on average, 2%. Cotrimoxazole or trimethoprim alone (which is mostly just as effective as cotrimoxazole as monotherapy for urinary tract infections) can be used for appropriate indications. In the case of necessary treatment with dapsone, an individual decision must be made about limiting breastfeeding. With ciprofloxacin, it was calculated that between 2% and 7% of the weight-related maternal dosage reaches the infant (Gardner 1992, Cover 1990, Giamarellou 1989). However, no ciprofloxacin could be detected in the serum of a breastfed infant (maternal serum concentration 0. Garenoxacin was given in a single dose of 600 mg to six women, who had already weaned. In the case of levofloxacin, a mother received 500 mg/day over 3 weeks, first parenterally and then orally. There are no data on the passage into the milk of cinoxacin, enoxacin, gatifloxacin, grepafloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, rosoxacin, and sparfloxacin. In animal studies, quinolones damage the cartilage in the joints irreversibly during the growing years. As a rule, a standard antibiotic with a lower potential for risk can easily be substituted for them. When a complicated infection (for example, of the urinary tract, or a pseudomonas infection) really requires a quinolone, whenever possible ciprofloxacin should be preferred and breastfeeding continued. For the infant, this represents about 6% of the maternal weight-related dosage, or 15% of the daily dosage for an infant. In a case report, hemorrhagic enteritis was described in an infant whose mother had taken clindamycin and gentamicin. The symptoms improved spontaneously after breastfeeding was interrupted (survey by Bennett 1996). With lincomycin, a maximum of 1% of the maternal weightrelated dosage was measured in the milk (Medina 1963). Peak values of up to 4 mg/kg daily, on average ­ only about 1% of the therapeutic infant dosage ­ pass into the milk (survey by Bennett 1996, Plomp 1983). Refusal of food and vomiting by the baby have been described in connection with maternal treatment (Havelka 1968). When it is unavoidable, clindamycin, vancomycin, and lincomycin, as well as colistin and polymyxin B, may be prescribed. Generally, an antibiotic with a lower risk potential can easily be substituted for it. This also applies following short-term usage of the urinary tract antiseptic discussed. Following a single oral dosage of 2 g for trichomoniasis, the highest concentration was found in the milk after 2­4 hours. This is on average around 21 mg/l; in a single case it reached 46 mg/l (Erickson 1981). In the plasma of breastfed children, 2 g/ml each of metronidazole and its metabolite hydroxymetronidazole were detected. Comparable results were found with a 9-day course of 1200 mg/d (Passmore 1988, Heisterberg 1983, Erickson 1981). There has as yet been no indication of experimentally observed mutagenic and carcinogenic effects of metronidazole in human beings. With trichomoniasis, metronidazole should be used in preference to the other nitroimidazoles. A single oral dose of 2 g is preferable to vaginal application spread over several days. Whenever possible, the administration of metronidazole should be in the evening after the last breastfeed in order to limit further the exposure during the nightly breastfeeding break. This also applies to intravenous administration spread over several days in cases where this really is urgently indicated. Weaning or interruption of breastfeeding with substitution of infant formula no longer seems justifiable based on the available experience. However, in 5 of the 10 newborns included in this study, gentamicin concentrations equivalent to 10% of the maternal values were measured in the serum. This leads to the conclusion that newborns absorb aminoglycosides enterally, or accumulate them due to reduced excretion, at levels that cannot be ignored. The other aminoglycoside antibiotics amikacin, neomycin, netilmicin, paromomycin, spectinomycin, and streptomycin have been insufficiently documented in this respect. When aminoglycosides are strongly indicated, they may be used during breastfeeding. Restricted use is particularly applicable to the early postnatal period, since both quantitative absorption and accumulation by the infant must be reckoned with and, at least in the case of streptomycin, an ototoxic effect cannot be ruled out. In the first case, the maternal daily dosage was 15 mg/kg; in the second case, no dosage is given (Snider 1984). A maximum of 5% of a weight-related therapeutic dosage of rifampicin is transmitted to the infant (Snider 1984). The aminoglycoside streptomycin can be expected to appear only in limited amounts in the milk and, apart from during the newborn period, is not absorbed enterally in any noteworthy amount (see section 4. Tuberculostatics of choice during breastfeeding are isoniazid (in combination with 0. Following oral administration of 600 mg chloroquine base to breastfeeding mothers, peak values of 4. With the very long half-life, continuing high plasma/milk levels can be expected despite weekly intake of malaria prophylaxis. Assuming a weekly (prophylactic) dosage of 500 mg chloroquine phosphate (which equals approximately a 300-mg chloroquine base), a weight-related dosage of just 1 mg/kg daily is calculated for the mother. According to two studies (Ette 1987, Edstein 1986), an average of between 1 and 12%(! However, despite the not insignificant transfer into the milk, symptoms have not yet been reported. Quinine too, which has experienced a renaissance in malaria therapy because of increasing resistance, is well-tolerated during breastfeeding. The experience with mefloquine to date is insufficient for a differentiated risk assessment during breastfeeding. There is no experience with artemisinin derivatives (arthemether), atovaquone, halofantrine primaquine, and other antimalarials. Prophylaxis and therapy of malaria is primarily oriented to drug resistance in the specific region or country. Usually therapy is short, and is therefore no indication in itself to interrupt breastfeeding. In case of prophylaxis for several weeks, a decision on cessation of breast feeding must be taken individually. At least, chloroquine, proguanil, quinine and a combination of sulfadoxin/ pyrimethamine as well as mefloquine are acceptable because of sufficient experience. Chloroquine and quinine should not be used during breastfeeding for other indications requiring long-term daily administration. For all practical purposes, they are not absorbed and are not available to the infant enterally. Extensive experience with their therapeutic use in infancy argues against any toxic potential. The same applies to miconazole, which is also, for all practical purposes, not absorbed.

Benzodiazepines with a longer half-life (up to several days) purchase genuine glyset on-line, such as chlordiazepoxide buy glyset now, clobazam 50 mg glyset purchase overnight delivery, clorazepate glyset 50 mg with visa, diazepam glyset 50 mg purchase fast delivery, flunitrazepam, flurazepam, ketazolam, medazepam, nitrazepam, nordazepam, and prazepam, are used mainly as sedatives and anxiolytics. There is controversy about the risk of malformations after exposure to benzodiazepines in the first trimester. Barbiturates were the most important hypnotics on the market, prior to the introduction of the benzodiazepines. Most experience with the use of barbiturates during pregnancy comes from women with epilepsy (see Chapter 2. Short-term use of barbiturates for sleeping disorders or for anesthesia is probably safe. When phenobarbitone is given near delivery, respiratory depression can occur in the neonate (Desmond 1972). Also, a recent casecontrol study found weak but statistical significant associations with oral clefts, intestinal atresia, and microcephaly after first-trimester exposure (Rodriguez-Pinilla 1999). However, other studies do not confirm this association (Erös 2002, Dolovich 1998, Ornoy 1998, Patuszak 1996). In a population-based case-control study, Czeizel (2003) did not find a detectable teratogenic risk to the fetus after maternal shortterm use (during approximately 3 weeks) of diazepam in the first trimester. For chlordiazepoxide, a somewhat higher risk of congenital cardiovascular malformations after intrauterine exposure in the second and third months cannot be excluded, according to Czeizel (2004). In a French registry of congenital malformations, 262 malformed infants with intrauterine exposure to benzodiazepines were found. Among them were six cases of anal atresia, five of which had been exposed to lorazepam. The authors state that this finding should be regarded as preliminary until it is confirmed in other data sets (Bonnot 2001). Limited data on alprazolam do not suggest a significant association with fetal malformations (Schick-Boschetto 1992, St Clair 1992). About 100 pregnancies exposed to clonazepam, 18 to medazepam, 18 to nitrazepam, and 13 to tofisopam were evaluated, but did not indicate teratogenicity (Lin 2004, Erös 2002). The regular use of benzodiazepines in the third trimester up to delivery may cause the "floppy infant syndrome" (sedation, muscular hypotonia, sucking problems, apnea, cyanosis, and hypothermia) and neonatal withdrawal symptoms. When strictly indicated, benzodiazepines are among the drugs of first choice for the treatment of anxiety and sleeping disorders during pregnancy. Observation of the neonate for respiratory depression, withdrawal symptoms or adaptation problems is recommended when benzodiazepines have been used up to delivery. A prospective controlled study on 40 first-trimester zopicloneexposed women found no increased rate of major malformations (Diav-Citrin 1999). Data for zaleplon and eszopiclone are insufficient to assess the safety in pregnancy. No data are available for the use of any of these drugs during pregnancy (see also Chapter 2. No increased incidence of malformations has been found, but more data are needed to exclude a possible teratogenic risk. Since the introduction of benzodiazepines, there are very few indications for its use in pregnant women. In the 1970s, the use of meprobamate in the first trimester was associated with a possible increase in cardiac defects and polydactyly, observed, for example, 310 2. Buspirone, kavain, hydroxyzine, meprobamate, and opipramol should be avoided during pregnancy. Inadvertent use is not an indication for a termination of pregnancy or invasive diagnostic procedures. Chloral hydrate is quickly metabolized to trichloroethanol and trichloroacetic acid. There are few data on its use in pregnancy, but to date no increased incidence of congenital malformations has been reported (Heinonen 1977). Its inadvertent use is not grounds for termination of pregnancy or for additional diagnostic procedures. The drugs of first choice for sleeping disorders are sedating antihistamines and benzodiazepines. Data on its use during pregnancy are not available, but there is no indication of prenatal toxicity in humans with this broadly used substance. However, there is substantial controversy concerning its use during pregnancy (see also Chapter 2. Clomethiazole is used to treat withdrawal symptoms after chronic abuse of alcohol. Chronic use of tryptophane during pregnancy has been associated with increased fetal breathing movements. Clomethiazol, melperone, promethazine, scopolamine, and tryptophane should not be prescribed to pregnant women with sleeping disorders. Inadvertent use of these drugs during pregnancy is not grounds for termination of pregnancy, or for invasive diagnostic procedures. The drugs of first choice for sleeping disorders are sedating antihistamines such as diphenhydramine, valerian, or benzodiazepines. The prototype is the centrally acting drug, amphetamine, which can lead to addiction. In about 50 pregnancies where methylphenidate had been used, no substantial indication for teratogenicity was found. An increased incidence of prematurity and growth retardation as well as neonatal withdrawal symptoms have been reported in infants of mothers abusing methylphenidate together with other substances (DeBooy 1993). It is important to be aware that this drug is increasingly prescribed not only during childhood but also to women of reproductive age for attention deficit and hyperactivity syndrome. Modafinil, with a different mode of action from amphetamines, is used for narcolepsy. Detailed fetal ultrasonography may be performed after recurrent or high-dose exposure in the first trimester. Parkinson drugs which are given also for juvenile parkinsonism and restless leg syndrome are l-dopa/ benserazide. Some 15 exposed pregnancies have been reported, with uneventful delivery of normal children. Parkinson drugs such as the dopamine agonists bromocriptine, cabergoline, -dihydroergocryptine, lisuride, and pergolide, are used in women of reproductive age to inhibit prolactin secretion. With the exception of the broadly used ergotamine derivatives, data are insufficient for risk assessment in pregnancy. There is a case report of a woman treated with high doses of pramipexol during pregnancy (Mucchiut 2004). Combined treatment of a neuroleptic drug with biperiden is acceptable in pregnancy when indicated. Inadvertent use of a Parkinson drug not belonging to the broadly used ergotamine derivatives is not grounds for termination of pregnancy, or for invasive diagnostic procedures. Detailed fetal ultrasonography may be considered where first-trimester exposure to less-used drugs has occurred. Cardiac arrhythmia in a newborn infant associated with fluoxetine use during pregnancy. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Maternal use of selective serotonin re-uptake inhibitors and risk for birth defects. Platelet serotonin in newborns and infants: ontogeny, heritability and effect on in utero exposure to selective serotonin reuptake inhibitors. Clozapine concentrations in maternal and fetal plasma, amniotic fluid and breast milk. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13 554 patients in England. Maternal exposure to lorazepam and anal atresia in newborns: results from a hypothesis-generating study of benzodiazepines and malformations. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. A population-based case-control study of oral chlordiazepoxide use during pregnancy and risk of congenital abnormalities. Pregnancy outcome following firsttrimester exposure to zopiclone: a prospective controlled cohort study. Pregnancy outcome after gestational exposure to loratadine or other antihistamines: a prospective controlled cohort study. Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. Mirtazapin (Remergil): Behandlungsoption bei therapieresistenter Hyperemesis gravidarum Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counseling. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. A population-based case-control study of nitrazepam, medazepam, tofisopam, alprazolam and clonazepam treatment during pregnancy. Bupropion Pregnancy Registry ­ Interim Report, 1 September 1997 through 28 February 2006. Mirtazapine use in resistant hyperemesis gravidarum: report of three cases and review of the literature. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. Serious life events and congenital malformations: a national study with complete follow-up. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Dose of selective serotonin reuptake inhibitors across pregnancy: clinical implications. Pregnancy, delivery and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Fetal abnormalities associated with high-dose tranylcypromine in two consecutive pregnancies Abstract. Neonatal toxicity and transient neurodevelopment deficits following prenatal exposure to lithium: another clinical report and a review of the literature. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. Neonatal abstinence syncrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. In: Y Lapierre, B Jones (eds), Clozapine in Treatment Resistant Schizophrenia: A Scientific Update. Neurodevelopmental outcome of infants and toddlers exposed prenatally to selective serotonin reuptake inhibitors. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. Effects of prenatal meprobamate and chlordiazepoxide hydrochloride on human embryonic and fetal development. Withdrawal symptoms in a neonatal infant following exposure to venlafaxine during pregnancy. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective controlled study. Child neurodevelopment following exposure to venlafaxine in utero, unexposed siblings as comparison group: preliminary results Abstract. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Prospective assessment of pregnancy outcome following first trimester exposure to benzodiazepines. Severe and prolonged sedation in five neonates due to persistence of active diazepam metabolites. A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. No complications with risperidone treatment before and throughout pregnancy and during the nursing period. Presentation at the 10th Annual Conference of the European Network of Teratology Information Services, 1999.

Endovenous mechanochemical ablation of great saphenous vein incompetence using the ClariVein device: a safety study buy discount glyset 50 mg online. Mechanochemical endovenous ablation of small saphenous vein insufficiency using the ClariVein device: one-year results of a prospective series discount glyset 50 mg amex. Revision of the venous clinical severity score: venous outcomes consensus statement best glyset 50 mg. Venous clinical severity score and quality-of-life assessment tools: application to vein practice buy cheap glyset 50 mg line. A study to compare disease-specific quality of life with clinical anatomical and hemodynamic assessments in patients with varicose veins buy generic glyset on-line. Cure and reappearance of symptoms of varicose veins after stripping operation: a 34 year follow-up. Recurrence after varicose vein surgery: a prospective long-term clinical study with duplex ultrasound scanning and air plethysmography. Recurrent varicose veins after surgery: a new appraisal of a common and complex problem in vascular surgery. Long-term outcomes of endovenous radiofrequency obliteration of saphenous reflux as a treatment for superficial venous insufficiency. Endovenous ablation (radiofrequency and laser) and foam sclerotherapy versus conventional surgery for great saphenous vein varices. Surgery and endovenous techniques for the treatment of small saphenous varicose veins: a review of the literature. A systematic review and metaanalysis of randomised controlled trials comparing endovenous ablation and surgical intervention in patients with varicose vein. Recurrent varicose veins and primary deep venous insufficiency: relationship and therapeutic implications. Saphenous surgery does not correct perforator incompetence in the presence of deep venous reflux. Surgical correction of main stem reflux in the superficial venoussystem: does it improve the blood flow of incompetent perforating veins Treatment of superficial and perforator venous incompetence without deep venous insufficiency: is routine perforator ligation necessary Effectiveness and safety of ultrasound-guided foam sclerotherapy for recurrent varicose veins: immediate results. Duplex ultrasound outcomes following ultrasound-guided foam sclerotherapy of symptomatic recurrent great saphenous varicose veins. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. Review and comment of the 2011 clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. Management of chronic venous disorders of the lower limbs­guidelines according to scientific evidence. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. When the obstruction occurs in the iliofemoral segment, postthrombotic morbidity is often severe. In a recent study, the intraluminal contents of chronically occluded postthrombotic common femoral veins were analyzed. In fact, randomized trials, registries, and large observational experiences have demonstrated a reduction in the incidence of postthrombotic syndrome after successful thrombus removal. Ambulatory venous hypertension is the underlying pathophysiology resulting from venous valvular incompetence and postthrombotic luminal obstruction. In this setting, compartment pressures can be used as a surrogate for venous pressures. Labropoulos et al5 measured arm-foot pressure gradients in patients with chronic postthrombotic venous disease. Patients with iliofemoral venous disease had the highest resting and postocclusive hyperemic pressures compared with patients with infra-inguinal postthrombotic disease. Unfortunately, a thrombus in the iliofemoral venous system frequently persists, causing central venous obstruction. This is largely due to persistent obstruction of the major venous outflow tract of the lower extremities. Antibodies to four biomarkers were used to examine the specific function of these endothelial cells. Luminal obstruction Based on ultrasound findings and phlebography, the obstructive nature of the thrombus in the vein lumen has been variously described as chronic thrombus, intraluminal fibrosis, or scar tissue. Until recently, no definitive description of the human tissue that chronically obstructs postthrombotic veins has been provided. In an attempt to resolve the extreme morbidity of these patients, those presenting with incapacitating postthrombotic syndrome due to chronic iliofemoral and inferior vena cava occlusion are fully evaluated. If the common femoral vein is obstructed, it is recommended to perform a common femoral vein endophlebectomy followed by transluminal recanalization of the occluded iliac veins and inferior vena cava (if involved). The neovascular channels were observed in the loose collagen, whereas few neovascular channels (if any) occurred within the densely packed collagen. An interesting observation was the close proximity of recanalization channels to neovessels. This suggests that two processes­neovascularization and revascularization­ are governed partly by a common stimulus. Which aspects of its many functions are operative in the earlier vs the later stages of thrombus resolution require further study. The answer to this question depends upon whether a strategy of thrombus removal is attempted and successful. The true question is "does a strategy of thrombus removal result in less postthrombotic morbidity They observed that iliofemoral venous patency was significantly better and venous pressures, leg edema, and postthrombotic morbidity were lower in patients randomized to venous thrombectomy. The evolution of catheter-based techniques has significantly reduced the need for venous thrombectomy. Integrating mechanical techniques with catheter-directed lysis has reduced the dose of the plasminogen activator, reduced the length of the hospital stay, and improved the efficiency of thrombus removal. Hematoxylin/eosin staining showing abundant collagen, neovascularization, recanalization, and inflammation in the common femoral vein. However, the neovessel endothelium was more densely stained than the recanalization endothelium. Posttreatment assessment of a patient with deep vein thrombosis treated by pharmacomechanical thrombolysis and stenting after unsuccessful anticoagulation. Photograph of a patient with severe acute phlegmasia cerulea dolens after 5 days of treatment with low-molecular-weight heparin (Panel A). Patency restoration to the femoral vein (Panel C) and the iliac venous system (Panel D) after pharmacomechanical thrombolysis. The patient had persistent obstruction of the common iliac vein, which was corrected with a 16-mm bare-metal stent (Panel E). At the 36-month follow-up, the physical examination was normal and the veins were patent with normal valve function (Panel F). The CaVenT (Catheter-directed Venous thrombolysis in acute iliofemoral vein Thrombosis) study investigators randomized patients to anticoagulation plus catheterdirected thrombolysis vs anticoagulation alone. Since the majority of patients entered into the trial had a patent iliac venous system, the number needed to treat to prevent one postthrombotic syndrome was seven. The final follow-up visits will occur in December 2016, at which time, the data will be analyzed, presented, and published. Of course, removing the acute thrombus will restore patency and eliminate the substrate for luminal obstruction, thereby significantly reducing the likelihood of severe postthrombotic morbidity. Venous function assessed during a 5 year period after acute ilio-femoral venous thrombosis treated with anticoagulation. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis Intramuscular pressure in the lower leg in deep vein thrombosis and phlegmasia cerulae dolens. The role of venous outflow obstruction in patients with chronic venous dysfunction. Endovenectomy of the common femoral vein and intraoperative iliac vein recanalization for chronic iliofemoral venous occlusion. A histological and functional description of the tissue causing chronic postthrombotic venous obstruction. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Thrombectomy with temporary arteriovenous fistula: the treatment of choice in acute iliofemoral venous thrombosis. Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula. Venous thrombectomy for iliofemoral vein thrombosis-10-year results of a prospective randomised study. Catheter-direct thrombolysis versus pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis. Catheterdirected thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. Postthrombotic morbidity correlates with residual thrombus following catheter-directed thrombolysis for iliofemoral deep vein thrombosis. Longterm outcome after additional catheterdirected thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. The positive impact of micronization on the pharmacological activity of purified flavonoid fraction has been demonstrated in both animal and clinical pharmacological trials. The use of plants and isolated phytochemicals for the prevention and treatment of various health ailments has been in practice for years. About 25% of the drugs prescribed worldwide are derived from plants and 121 such active compounds are currently in use. Flavonoids have been reported to chelate metal, inhibit enzymes, inhibit cellular proliferation, induce apoptosis, stabilize membranes, and scavenge free radicals. Flavonoids have antioxidant, anti-inflammatory, antiallergic, antibacterial, osteogenic, cytotoxic, antitumoral, hepatoprotective, antithrombotic, and antiviral pharmacological properties. Registered as: Alvenor, Ardium, Arvenum 500, Capiven, Daflon 500 mg, Daflon 1000 mg, Detralex, Elatec, Flebotropin, Variton, Venitol. The fruit are harvested when they fall from the tree at the end of the flowering period. To date, more than 4000 flavonoids have been identified and they are widely distributed in the leaves, seeds, bark, and flowers of plants that constitute an integral part of the human diet. The most important groups are the anthocyanidins, catechins, flavones, flavanones, and flavonols (Table I). Microcrystalline cellulose is an inert substance that is widely used as a binder and diluent in many pills and tablets. Microcrystalline cellulose has no impact on the dissolution rate of any active ingredients; consequently, it cannot improve their absorption and cannot replace the benefits of the micronization 2. Sodium starch glycolate is derived from potato starch, is not contraindicated for celiac disease, and is a disintegrant. It has a bovine, ovine, or poultry origin; therefore, it is compatible with the Muslim religion and a gout diet. In a hamster model of venous inflammation, where leaky sites are formed in the cheek pouch, each of these additional flavonoids administered separately displayed an antileakage effect comparable to or greater than diosmin. Absorption of compounds derived from diosmin metabolism, measured by the urinary excretion of total radioactivity following oral administration of 14C-diosmin in humans, was significantly (P=0. The positive impact of micronization on the pharmacological activity of purified flavonoid fraction has been demonstrated in both preclinical and clinical pharmacological trials. Metabolism studies showed that diosmin is metabolized by gut microbiota within the gastrointestinal tract to produce several metabolites 85 Phlebolymphology - Vol 23. Illustrations of a normal venous valve without reflux (Panel A), a valve with a nonpathological commissural reflux usually seen in the evening after being in a prolonged upright position (Panel B), and a valve with a pathological intervalvular reflux (Panel C). Such inflammatory processes start with inappropriate activation of leukocytes in the veins. A total of 41 C0s patients were enrolled, and, of these patients, 15 had no reflux in either the morning or evening and 26 had transitory evening reflux with 22 being commissural and 4 intervalvular. The saphenous vein diameter was greater in the subgroup of patients with transitory reflux compared with patients without reflux (P<0. For most measurements, the results obtained with four tablets were significantly reinforced compared with those obtained with two tablets, but the effect was not doubled. In this analysis, the incidence of adverse events was not significantly different in patients >70 years old or with concomitant diseases (ie, hypertension, atherosclerosis, diabetes mellitus, neurological/psychiatric disease, or alcoholism) than the total population group. The only nonsignificant effects were for itching, but the sample size was the lower (n<500). The placebo effect in these studies is far from being insignificant and thus large samples are needed to observe any treatment effect on venous symptoms. Rabe et al showed that approximately 20% of all patients consulting their general practitioner for any reason could be assigned to class C0s; therefore, it is important to treat these patients effectively. Benefits of the micronized purified flavonoid fraction on symptoms and quality of life of C3 and C4 patients. Venous edema is described as sporadic, unilateral or bilateral, and more frequently located at the ankle. An ideal treatment would rapidly and significantly reduce symptoms, stop disease progression, act on all components of the Email: arnaud. A review on pharmacological and analytical aspects of diosgenin: a concise report. A review on pharmacological and analytical aspects of diosmetin: a concise report. Different flavonoids present in the micronized purified flavonoid fraction (Daflon 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation. Confirmation of diosmetin 3-O-glucuronide as major metabolite of diosmin in humans, using micro-liquidchromatography-mass spectrometry and ion mobility mass spectrometry. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting.

References

• Gomez RG, Ceballos L, Coburn M, et al. Consensus statement on bladder injuries. BJU Int. 2004;94(1):27-32.
• Fletcher CDM, Bridge JA, Hogendoorn P, et al., eds. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon, France: IARC Press; 2013.
• Fillinger MF, Racusin J, Baker RK, et al: Anatomic characteristics of ruptured abdominal aortic aneurysm of conventional CT scans: implications for rupture risk, J Vasc Surg 39:1243, 2004.
• Godaly G, Carlsson O, Broman M. Phoxilium((R)) reduces hypophosphataemia and magnesium supplementation during continuous renal replacement therapy. Clin Kidney J. 2016;9: 205-210.
• Bruner A, Norris TW: Age-related changes in caloric nystagmus. Acta Otolaryngol Suppl 282:1-24, 1971.
• Kwok JC, Afshari F, Garcia-Alias G, et al: Proteoglycans in the central nervous system: plasticity, regeneration and their stimulation with chondroitinase ABC, Restor Neurol Neurosci 26(2-3):131-145, 2008.
• Anderson JL, Adams CD, Antman EM, et al: ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarctionexecutive summary. A Report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-St-elevation myocardial infarction) Developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:652-726.
• Williams-Johnson J, Williams E. Sickle cell disease and other hereditary hemolytic anemias. In: Tintinalli JE, Kelen GD, Stapczynski JS, editors. Emergency medicine: a comprehensive study guide. 7th ed. New York: McGraw- Hill; 2011.